deltatrials
Terminated PHASE2 NCT00242827

Efficacy and Safety of Oral CEP-701 for the Treatment of Patients With Advanced Multiple Myeloma

An Open-Label Study of the Efficacy and Safety of Oral CEP-701 for the Treatment of Patients With Advanced Multiple Myeloma

Sponsor: Cephalon

Conditions Myeloma
Interventions Oral CEP-701
Updated 6 times since 2017 Last updated: Aug 22, 2012 Started: Apr 30, 2006 Completion: May 31, 2007

A PHASE2 clinical study on Myeloma, this trial is terminated or withdrawn. The trial is conducted by Cephalon and has accumulated 6 data snapshots since 2006. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Change History

6 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  3. Jan 2022 — Jul 2024 [monthly]

    Terminated PHASE2

  4. Jan 2021 — Jan 2022 [monthly]

    Terminated PHASE2

  5. Jun 2018 — Jan 2021 [monthly]

    Terminated PHASE2

▶ Show 1 earlier version

  1. Jan 2017 — Jun 2018 [monthly]

    Terminated PHASE2

    First recorded

Apr 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Cephalon
Data source: Teva Branded Pharmaceutical Products R&D, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Atlanta, United States
  • • Hackensack, United States
  • • Indianapolis, United States
  • • New York, United States
  • • Philadelphia, United States